Aprotinin Used In Heart Surgery Associated With Increased Risk Of Death, Study Shows

Aprotinin is associated with a 50 percent increase in the relative risk of death, according to a major Canadian clinical trial comparing three drugs routinely used to prevent blood loss during heart surgery. The trial shows that approximately six per cent of patients who received aprotinin died within 30 days of surgery compared to four per cent of patients who received tranexamic acid or aminocaproic acid.

Read the whole article on Science Daily

More from Science Daily